Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medivation Gets $110M Upfront From Astellas In Prostate Cancer Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

As in its Dimebon collaboration with Pfizer, the biotech gets significant U.S. profit-sharing along with an option for co-promotion.
Advertisement

Related Content

With Muted Expectations For Provenge, Dendreon Restructures, Cuts Staff
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
Big Pharma Talks Deal-Making Risk At TAP
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
Several Prostate Cancer Drug Candidates Heading Into Home Stretch
Several Prostate Cancer Drug Candidates Heading Into Home Stretch

Topics

Advertisement
UsernamePublicRestriction

Register

PS068664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel